Dymicron Triadyme-C Cervical Artificial Disc
OREM, Utah, Jan. 15, 2026 /PRNewswire/ — Dymicron®, a privately held medical device company pioneering advanced spinal technologies, today announced the successful enrollment and treatment of the first patient in its Triadyme®-C Investigational Device Exemption (IDE) clinical trial. This milestone marks the start of a US clinical study evaluating the safety and effectiveness of the Triadyme-C cervical artificial disc.
The first procedure was performed by Armen Khachatryan, MD, board-certified spine surgeon and founder and director of the Disc Replacement Center in South Jordan, Utah. “The first American procedure with Triadyme-C was performed successfully and the patient is doing well,” said Dr. Khachatryan. “The Triadyme-C disc is a revolutionary cervical artificial disc with a unique polycrystalline diamond surface that allows its unique trilobar design to mimic the natural motion of a spinal segment. I look forward to evaluating clinical and radiographic outcomes as enrollment in the IDE study continues.”
The Triadyme–C device features bearing surfaces made from Adymite™, Dymicron’s patented medical-grade polycrystalline diamond technology. Adymite is designed to dramatically reduce the generation of wear debris compared to conventional implant materials such as titanium, cobalt chrome and polyethylene, a problem related to long-term device complications and revision surgeries. The result is a device with exceptional toughness, low friction, and long-term joint performance, optimized for the demands of preserving spinal motion throughout its life.
“Enrollment of the first patient in our Triadyme-C IDE trial represents an important milestone for Dymicron and underscores years of focused innovation and validation,” said Alan S. Layton, CEO and Chairman of the Board of Dymicron. “This achievement reflects the dedication of our team and clinical partners, and brings us one step closer to providing American surgeons and patients with a next-generation artificial cervical disc designed to preserve motion while addressing the limitations of existing technologies.”
The IDE trial was designed to evaluate clinical and radiographic outcomes in patients with cervical degenerative disc disease requiring surgical intervention. The Triadyme-C IDE clinical trial will enroll patients at multiple research sites in the United States. Data from the study will support Dymicron’s evaluation of Triadyme-C as an artificial cervical disc intended to preserve motion and support long-term function.
About Triadym-C
The Triadyme-C is a next-generation, motion-preserving cervical artificial disc made from Adymite (polycrystalline diamond), one of the most wear-resistant materials known to man. As a result, Triadyme-C produces virtually no detectable wear debris, minimizing the risk of wear debris-related complications and optimizing performance throughout the patient’s life. The Triadyme-C’s patented trilobar articulating surfaces are designed to mimic the natural kinematics and motion of a spinal disc.
About Dymicron
Dymicron is a privately held, innovation-driven medical device company headquartered in Orem, Utah. The company has developed a revolutionary next-generation total disc replacement system for the cervical spine engineered from Adymite, its proprietary medical-grade polycrystalline diamond material. For more information, visit http://www.dymicron.com/.
For more information, please contact:
Curt Ence
CFO
1186 South 1680
West Orem, Utah 84058
Email: IR@dymicron.com
SOURCE Dymicron Inc.
